Document Detail

Tolerability and well-being with metoprolol in a controlled release (CR/ZOK) formulation: a review article.
MedLine Citation:
PMID:  2179287     Owner:  NLM     Status:  MEDLINE    
Extensive research and clinical usage of metoprolol have shown the compound to be safe and well tolerated if the contraindications are taken into consideration. However, as with other beta-blockers, unwanted effects may occur during treatment. Although usually mild, these side effects may be of considerable clinical importance, especially since once initiated, therapy is often life-long. Results of previous studies have indicated that some of these symptoms are associated with high plasma concentrations of the drug. Theoretically, side effects may thus be reduced by administration of metoprolol in a controlled-release formulation (CR/ZOK) which yields relatively low plasma concentrations over approximately 24 hours. Using clinically relevant doses, metoprolol CR/ZOK affects beta 2-adrenoceptor-mediated functions (e.g., broncho-dilatation in asthmatics) less than tablets do. In addition, less leg fatigue during exercise has been reported. The clinical studies published so far indicate that metoprolol CR/ZOK is as well tolerated as or better tolerated than, conventional metoprolol tablets. Furthermore, metoprolol CR/ZOK is tolerated equally or better than atenolol in terms of CNS-related symptoms.
E Dimenäs; C Dahlöf
Related Documents :
6118127 - Static exercise in anesthetized dogs, a cause of reflex alpha-adrenergic coronary vasoc...
12447337 - Electrocardiographic changes associated with beta-blocker toxicity.
8307847 - Autonomic regulation of heart rate response to exercise in tibetan and han residents of...
3538777 - Tolerance development as a pharmacological and clinical problem.
1830847 - Influence of exercise on dehydroepiandrosterone sulphate and delta 4-androstenedione pl...
7928917 - Loss of diaphragm glutathione is associated with respiratory failure induced by resisti...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of clinical pharmacology     Volume:  30     ISSN:  0091-2700     ISO Abbreviation:  J Clin Pharmacol     Publication Date:  1990 Feb 
Date Detail:
Created Date:  1990-04-26     Completed Date:  1990-04-26     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0366372     Medline TA:  J Clin Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S92-7     Citation Subset:  IM    
Research Laboratories, AB Hässle, Mölndal, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Central Nervous System Diseases / chemically induced*,  physiopathology
Delayed-Action Preparations
Drug Tolerance
Hypertension / drug therapy,  physiopathology
Metoprolol / administration & dosage,  adverse effects*,  therapeutic use
Reg. No./Substance:
0/Delayed-Action Preparations; 37350-58-6/Metoprolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of CNS-related subjective symptoms in hypertensive patients treated with either a new con...
Next Document:  Rapid-acting parenteral antihypertensive agents.